Compare F5 Inc (FFIV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Sana Biotechnology Inc — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: F5 Inc is far larger — about 31.2× Sana Biotechnology Inc's market cap, and F5 Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Sana Biotechnology Inc for 23 Days on average.
| FFIV | SANA | |
|---|---|---|
Market Cap | $26.14B | $836.71M |
Volume | 503,146 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $479.83 | $5.92 |
52-Week Low | $223.99 | $2.68 |
Typical Hold Time | 38 Days | 23 Days |
Enterprise Value | $24.78B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.73 surpassing the $4.00 consensus, and maintains robust profitability with a net income margin of 21.95%. Recent news highlights leadership in WAAP platforms and AI security partnerships, reinforcing growth prospects.
The stock offers upside potential driven by earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 36.78 suggest premium pricing. Key risks include competitive pressures and market volatility, while analyst consensus leans neutral with a $416.60 price target below the current price, indicating cautious optimism tempered by valuation concerns.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
